Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 4/2010

01-08-2010 | Original Paper

Modeling stroke management: a qualitative review of cost-effectiveness analyses

Authors: Chantal Guilhaume, Delphine Saragoussi, John Cochran, Clément François, Mondher Toumi

Published in: The European Journal of Health Economics | Issue 4/2010

Login to get access

Abstract

Objective

To review recent economic analyses and determine if means of improving methodology used in modeling stroke management may exist.

Study design and setting

The Medline database was searched for pharmacoeconomic models of treatments or interventions in acute, non-transitory ischemic stroke. Search terms were: stroke, cost, cost-effectiveness, cost analysis, stroke management, model, modeling, and economic. All English-language articles published from January 1997 to January 2008 were reviewed.

Results

Ten Markov models and three decision analytical models were identified. All models had a societal perspective and all but one had lifetime horizons. They were all based on common patient states of disability, mortality and recurrence of stroke. Inputs used in the models were transparent and valid. Intracranial hemorrhage, cardiovascular events and data closely related to local settings were not systematically considered. One-way sensitivity analyses were the most common, but few parameters were tested and these varied between models. Consensus key drivers were therefore difficult to determine.

Conclusion

The overall structure of the models reviewed was sound. However, they should include more systematically cardiovascular events and intracranial hemorrhage, as well as local epidemiological data. Further multi-way sensitivity analyses would help to identify key cost drivers with greater precision and robustness.
Literature
1.
Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S.M., Ho, M., Howard, V., Kissela, B., Kittner, S., Lloyd-Jones, D., McDermott, M., Meigs, J., Moy, C., Nichol, G., O’Donnell, C., Roger, V., Sorlie, P., Steinberger, J., Thom, T., Wilson, M., Hong, Y.: Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), 25–146 (2008)CrossRef
2.
Wolfe, C.D., Giroud, M., Kolominsky-Rabas, P., Dundas, R., Lemesle, M., Heuschmann, P., Rudd, A.: Variations in stroke incidence and survival in 3 areas of Europe. European Registries of Stroke (EROS) Collaboration. Stroke 31(9), 2074–2079 (2000)
3.
Mayo, N.E., Wood-Dauphinee, S., Ahmed, S., Gordon, C., Higgins, J., McEwen, S., Salbach, N.: Disablement following stroke. Disabil. Rehabil. 21(5–6), 258–268 (1999)
4.
Van Den Bos, G.A.M.: The burden of chronic diseases in terms of disability, use of health care and healthy life expectancies. Eur. J. Public Health 5(1), 29–34 (1995)CrossRef
5.
Patel, M.D., Tilling, K., Lawrence, E., Rudd, A.G., Wolfe, C.D., McKevitt, C.: Relationships between long-term stroke disability, handicap and health-related quality of life. Age Ageing 35(3), 273–279 (2006)CrossRef
6.
Haacke, C., Althaus, A., Spottke, A., Siebert, U., Back, T., Dodel, R.: Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 37(1), 193–198 (2006)CrossRef
7.
Pohjasvaara, T., Vataja, R., Leppavuori, A., Kaste, M., Erkinjuntti, T.: Cognitive functions and depression as predictors of poor outcome 15 months after stroke. Cerebrovasc. Dis. 14(3–4), 228–233 (2002)CrossRef
8.
Kolominsky-Rabas, P.L., Heuschmann, P.U., Marschall, D., Emmert, M., Baltzer, N., Neundorfer, B., Schoffski, O., Krobot, K.J.: Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen stroke project. Stroke 37(5), 1179–1183 (2006)CrossRef
9.
Sandercock, P., Berge, E., Dennis, M., Forbes, J., Hand, P., Kwan, J., Lewis, S., Lindley, R., Neilson, A., Thomas, B., Wardlaw, J.: A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol. Assess. 6(26), 1–112 (2002)
10.
Chambers, M.G., Koch, P., Hutton, J.: Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 5(2), 82–97 (2002)CrossRef
11.
Ehlers, L., Andersen, G., Clausen, L.B., Bech, M., Kjolby, M.: Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 38(1), 85–89 (2007)CrossRef
12.
Ehlers, L., Muskens, W.M., Jensen, L.G., Kjolby, M., Andersen, G.: National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness. CNS Drugs 22(1), 73–81 (2008)CrossRef
13.
Fagan, S.C., Morgenstern, L.B., Petitta, A., Ward, R.E., Tilley, B.C., Marler, J.R., Levine, S.R., Broderick, J.P., Kwiatkowski, T.G., Frankel, M., Brott, T.G., Walker, M.D.: Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA stroke study group. Neurology 50(4), 883–890 (1998)
14.
Hallan, S., Asberg, A., Indredavik, B., Wideroe, T.E.: A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke. J. Intern. Med. 246(6), 549–559 (1999)CrossRef
15.
Launois, R., Giroud, M., Megnigbeto, A.C., Le Lay, K., Presente, G., Mahagne, M.H., Durand, I., Gaudin, A.F.: Estimating the cost-effectiveness of stroke units in France compared with conventional care. Stroke 35(3), 770–775 (2004)CrossRef
16.
Mar, J., Begiristain, J.M., Arrazola, A.: Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc. Dis. 20(3), 193–200 (2005)CrossRef
17.
Mihalopoulos, C., Cadilhac, D.A., Moodie, M.L., Dewey, H.M., Thrift, A.G., Donnan, G.A., Carter, R.C.: Development and application of model of resource utilization, costs, and outcomes for stroke (MORUCOS): an Australian economic model for stroke. Int. J. Technol. Assess. Health Care 21(4), 499–505 (2005)CrossRef
18.
Samsa, G.P., Reutter, R.A., Parmigiani, G., Ancukiewicz, M., Abrahamse, P., Lipscomb, J., Matchar, D.B.: Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J. Clin. Epidemiol. 52(3), 259–271 (1999)CrossRef
19.
Samsa, G.P., Matchar, D.B., Williams, G.R., Levy, D.E.: Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the stroke treatment with ancrod trial (STAT). J. Eval. Clin. Pract. 8(1), 61–70 (2002)CrossRef
20.
Sandercock, P., Berge, E., Dennis, M., Forbes, J., Hand, P., Kwan, J., Lewis, S., Lindley, R., Neilson, A., Wardlaw, J.: Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 35(6), 1490–1497 (2004)CrossRef
21.
Sinclair, S.E., Frighetto, L., Loewen, P.S., Sunderji, R., Teal, P., Fagan, S.C., Marra, C.A.: Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 19(9), 927–936 (2001)CrossRef
22.
Wardlaw, J.M., Seymour, J., Cairns, J., Keir, S., Lewis, S., Sandercock, P.: Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. Stroke 35(11), 2477–2483 (2004)CrossRef
23.
Bonita, R., Beaglehole, R.: Recovery of motor function after stroke. Stroke 19(12), 1497–1500 (1988)
24.
Collin, C., Wade, D.T., Davies, S., Horne, V.: The Barthel ADL index: a reliability study. Int. Disabil. Stud. 10(2), 61–63 (1988)
25.
Gresham, G.E., Phillips, T.F., Labi, M.L.: ADL status in stroke: relative merits of three standard indexes. Arch. Phys. Med. Rehabil. 61(8), 355–358 (1980)
26.
Loewen, S.C., Anderson, B.A.: Predictors of stroke outcome using objective measurement scales. Stroke 21(1), 78–81 (1990)
27.
Mahoney, F.I., Barthel, D.W.: Functional evaluation: the barthel index. Md. State Med. J. 14, 61–65 (1965)
28.
Rankin, J.: Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott. Med. J. 2(5), 200–215 (1957)
29.
van Swieten, J.C., Koudstaal, P.J., Visser, M.C., Schouten, H.J., van Gijn, J.: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5), 604–607 (1988)
30.
Briggs, A., Claxton, K., Sculpher, M.: Decision modelling for health economic evaluation (Handbooks in health economic evaluation). Oxford University Press, Oxford (2006)
31.
Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)
32.
Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581–1587 (1995)CrossRef
33.
Hacke, W., Kaste, M., Fieschi, C., Toni, D., Lesaffre, E., von Kummer, R., Boysen, G., Bluhmki, E., Hoxter, G., Mahagne, M.H., et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13), 1017–1025 (1995)CrossRef
34.
Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., Trouillas, P.: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 352(9136), 1245–1251 (1998)CrossRef
35.
Gage, B.F., Cardinalli, A.B., Owens, D.K.: The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch. Intern. Med. 156(16), 1829–1836 (1996)CrossRef
36.
Solomon, N.A., Glick, H.A., Russo, C.J., Lee, J., Schulman, K.A.: Patient preferences for stroke outcomes. Stroke 25(9), 1721–1725 (1994)
37.
Lee, A.J., Huber, J., Stason, W.B.: Post stroke rehabilitation in older Americans. The medicare experience. Med. Care 34(8), 811–825 (1996)CrossRef
38.
Weiner, J.M., Illston, L.H., Hanley, R.J.: Sharing the burden: strategies for public and private long-term care insurance. Brokings Institute, Washington, DC (1993)
39.
Hallan, S., Asberg, A., Indredavik, B., Wideroe, T.E.: Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes. J. Intern. Med. 246(3), 309–316 (1999)CrossRef
40.
Wardlaw J.M., Zoppo G., Yamaguchi T., Berge E.: Thrombolysis for acute ischaemic stroke. Cochrane database. Syst. Rev. 3, CD000213 (2003)
41.
Kwiatkowski, T.G., Libman, R.B., Frankel, M., Tilley, B.C., Morgenstern, L.B., Lu, M., Broderick, J.P., Lewandowski, C.A., Marler, J.R., Levine, S.R., Brott, T.: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N. Engl. J. Med. 340(23), 1781–1787 (1999)CrossRef
42.
Dewey, H.M., Thrift, A.G., Mihalopoulos, C., Carter, R., Macdonell, R.A., McNeil, J.J., Donnan, G.A.: Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 32(10), 2409–2416 (2001)CrossRef
43.
Samsa, G.P., Matchar, D.B., Goldstein, L., Bonito, A., Duncan, P.W., Lipscomb, J., Enarson, C., Witter, D., Venus, P., Paul, J.E., Weinberger, M.: Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am. Heart J. 136(4 Pt 1), 703–713 (1998)CrossRef
44.
Sherman, D.G., Atkinson, R.P., Chippendale, T., Levin, K.A., Ng, K., Futrell, N., Hsu, C.Y., Levy, D.E.: Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke treatment with ancrod trial. JAMA 283(18), 2395–2403 (2000)CrossRef
45.
Counsell, C., Dennis, M., McDowall, M., Warlow, C.: Predicting outcome after acute and subacute stroke: development and validation of new prognostic models. Stroke 33(4), 1041–1047 (2002)CrossRef
46.
Dorman, P., Dennis, M., Sandercock, P.: Are the modified “simple questions” a valid and reliable measure of health related quality of life after stroke? United Kingdom collaborators in the international stroke trial. J. Neurol. Neurosurg. Psychiatry 69(4), 487–493 (2000)CrossRef
Metadata
Title
Modeling stroke management: a qualitative review of cost-effectiveness analyses
Authors
Chantal Guilhaume
Delphine Saragoussi
John Cochran
Clément François
Mondher Toumi
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 4/2010
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-010-0228-4

Other articles of this Issue 4/2010

The European Journal of Health Economics 4/2010 Go to the issue

Original Paper

Geographic distribution of physicians in Portugal

Original Paper

Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences

Original Paper

Adverse selection in the health insurance market: some empirical evidence

Original Paper

The challenge of corporatisation: the experience of Portuguese public hospitals

Original Paper

Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain

Original Paper

Substituting inpatient for outpatient care: what is the impact on hospital costs and efficiency?